KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Assets: 2018-2024

Historic Assets for Adaptive Biotechnologies (ADPT) over the last 7 years, with Dec 2024 value amounting to $539.4 million.

  • Adaptive Biotechnologies' Assets fell 12.16% to $490.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $490.6 million, marking a year-over-year decrease of 12.16%. This contributed to the annual value of $539.4 million for FY2024, which is 18.42% down from last year.
  • Latest data reveals that Adaptive Biotechnologies reported Assets of $539.4 million as of FY2024, which was down 18.42% from $661.1 million recorded in FY2023.
  • Adaptive Biotechnologies' 5-year Assets high stood at $1.1 billion for FY2020, and its period low was $539.4 million during FY2024.
  • Moreover, its 3-year median value for Assets was $661.1 million (2023), whereas its average is $685.7 million.
  • Per our database at Business Quant, Adaptive Biotechnologies' Assets grew by 22.37% in 2020 and then decreased by 22.82% in 2023.
  • Over the past 5 years, Adaptive Biotechnologies' Assets (Yearly) stood at $1.1 billion in 2020, then fell by 17.29% to $923.3 million in 2021, then declined by 7.23% to $856.6 million in 2022, then dropped by 22.82% to $661.1 million in 2023, then fell by 18.42% to $539.4 million in 2024.